Tiziana Life Sciences: Funding, Investors & Team (Oct 2026)
Tiziana Life Sciences plc is a biotechnology company based in the UK that specializes in discovering and developing new molecules for treating human diseases in the fields of oncology and immunology. The company is currently focused on milciclib, a compound that inhibits specific enzymes known as cyclin-dependent kinases (CDK) and other protein kinases involved in cell division. Milciclib is currently in phase II clinical trials for treating epithelial thymic carcinoma and/or thymoma in patients who have undergone chemotherapy, and the company has also filed an Investigational New Drug (IND) application to conduct an exploratory trial for Hepatic Cellular Carcinoma (HCC).
Tiziana Life Sciences has raised $12.8M across 3 funding rounds on record, the most recent an undisclosed round of $8.8M announced in Jan 2026.
That round is in line with the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tiziana Life Sciences Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Tiziana Life Sciences Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Tiziana Life Sciences raised $4.0M in an undisclosed round announced in Sep 2024.
1.2 years later, an undisclosed round was announced in Nov 2025 with no disclosed amount.
2 months later, an undisclosed round of $8.8M was announced in Jan 2026.
Tiziana Life Sciences Founders and Leadership Team
Contact details for the Tiziana Life Sciences team: 1 of 2 have an email address on file.
Start 14-day free trial →Tiziana Life Sciences Funding Compared to Other Biotechnology Startups
Tiziana Life Sciences' latest round of $8.8M is in line with the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tiziana Life Sciences in Biotechnology and London
Companies Similar to Tiziana Life Sciences
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Tiziana Life Sciences Funding FAQs
What does Tiziana Life Sciences do?
Tiziana Life Sciences plc is a biotechnology company based in the UK that specializes in discovering and developing new molecules for treating human diseases in the fields of oncology and immunology. The company is currently focused on milciclib, a compound that inhibits specific enzymes known as cyclin-dependent kinases (CDK) and other protein kinases involved in cell division. Milciclib is currently in phase II clinical trials for treating epithelial thymic carcinoma and/or thymoma in patients who have undergone chemotherapy, and the company has also filed an Investigational New Drug (IND) application to conduct an exploratory trial for Hepatic Cellular Carcinoma (HCC).
How much funding has Tiziana Life Sciences raised?
Tiziana Life Sciences has raised $12.8M across 3 rounds on record. The most recent is an undisclosed round of $8.8M announced in Jan 2026.
When did Tiziana Life Sciences last raise funding?
Tiziana Life Sciences' most recent funding round on record is an undisclosed round of $8.8M, announced in Jan 2026.
Who founded Tiziana Life Sciences?
FundedIQ lists Gabriele Cerrone (Founder), Ivor Elrifi (Founder) at Tiziana Life Sciences.
Where is Tiziana Life Sciences headquartered?
Tiziana Life Sciences is based in London, England, United Kingdom.
How many employees does Tiziana Life Sciences have?
Tiziana Life Sciences is in the 1-10 employee band.
How does Tiziana Life Sciences' funding compare to other Biotechnology startups?
Tiziana Life Sciences' latest round of $8.8M is in line with the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Tiziana Life Sciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tiziana Life Sciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.